Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival.

ABSTRACT:

Purpose

Long-term estrogen inhibition may cause fatty liver disease (non-alcoholic fatty liver disease; NAFLD) among other adverse conditions such as osteoporosis, climacteric symptoms, thromboembolism, dyslipidemia, and metabolic syndrome. The prevalence of NAFLD among breast cancer patients ranges from 2.3%-45.2%. This study aimed to determine the risk factors for newly developed NAFLD among breast cancer patients after hormonal treatment and whether it influences survival outcomes.

Methods

This retrospective study investigated hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-), nonmetastatic breast cancer patients diagnosed between January 2010 and December 2018. All patients received adjuvant hormonal treatment for at lea

SUBMITTER: Taroeno-Hariadi KW 

PROVIDER: S-EPMC8561135 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature